

DID YOU KNOW TIME IN RANGE IMPACTS YOUR DIABETES?

Guardian™ Connect smart* continuous glucose monitoring (CGM) can help you stay in range



MORE THAN HALF OF PEOPLE


with diabetes are very worried about the risk of hypoglycemia.¹

Unpredictable glucose levels have a significant negative impact on daily life for 40% of people

using multiple daily injections (MDI) to manage their diabetes.²




TIME IN RANGE (TIR): The amount of time a person spends in their target range, **70-180 mg/dL** is the standard.



MORE TIME IN RANGE


People who used Guardian™ Connect to manage their diabetes spent an **average of 61.4% of their Time in Range over a 9-month period.**³

Spending more Time in Range **helps minimize complications**⁴ from going too high or too low.




PEOPLE WHO USED PREDICTIVE ALERTS⁴:

Experienced fewer high events
39%
of the time
vs. 10%
without alerts



Experienced fewer low events
60%
of the time
vs. 33%
without alerts



With the Guardian™ Connect CGM system, **you can better manage your Time in Range by setting customizable, predictive alerts** to notify you when sensor glucose levels are predicted to go too high or too low — **up to 60 minutes in advance.**

To learn more about Guardian™ Connect Smart CGM, visit medtronicdiabetes.com/GC

Medtronic
Further, Together

References

* Smart CGM predicts future high and low sensor glucose events up to 60 minutes in advance and provides access to Sugar.IQ™ insights that can inform users of clinically relevant glucose patterns.

¹ Nicolucci A, Kovacs Burns K, et al. Research: Educational and Psychological Issues Diabetes Attitudes, Wishes and Needs second study. *Diabet Med*. 2013;30:767–777.

² Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system. *Diabetes Care*. 2001;24(12):2030–2034.

³ Cohen O. Guardian™ Connect CGM: Why prediction, education and data interpretation are key for sustained better outcomes. Presented at: 11th International Conference on Advanced Technologies & Treatments for Diabetes; February, 2018; Vienna, Austria.

⁴ Cohen O, et al. ePoster presented at: 11th International Conference on Advanced Technologies & Treatments for Diabetes; February, 2018; Vienna, Austria. Abstract ATTD8-0288.

IMPORTANT SAFETY INFORMATION: GUARDIAN™ CONNECT CGM SYSTEM

The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at www.medtronicdiabetes.com/support/download-library/user-guides and www.medtronicdiabetes.com/importantsafetyinformation.

Medtronic

Medtronic Diabetes

18000 Devonshire Street
Northridge, CA 91325
1-800-646-4633

medtronicdiabetes.com

UC201811944 EN 940M18684-011 08JUNE2018 © 2018 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.